Vitamin C for treating atrial fibrillation

[Withdrawal from publication]

Harri Hemilä, Timo Suonsyrjä

Tutkimustuotos: ArtikkelijulkaisuMuu artikkeliTieteellinenvertaisarvioitu

Kuvaus

The Cochrane editors statement is shown below.However, there is no description why the topic has low priority. We found strong evidence that in RCTs published so far, vitamin C has prevented atrial fibrillation outside of the USA. Thus, was the low priority caused by effects seen only outside of the USA or because vitamin C is not interesting in the view of the Cochrane editors. The manuscript for the Cochrane review is available at: http://www.mv.helsinki.fi/home/hemila/H/HH_2015_CochAF_Protocol.pdf. The review was not rejected because of valid scientific reasons, see responses to reviewer comments at: http://www.mv.helsinki.fi/home/hemila/H/VitC_AF_1308_reviewer_comments.pdf. A shortened version was published in BMC Cardiovascular Disorders: https://doi.org/10.1186/s12872-017-0478-5. ## Reason for withdrawal from publication: The CRG withdrew this protocol as the current author team is unable to progress to the final stage of the review. The editors consider this title as low priority for the current portfolio of the Heart Group and therefore this title is not open to a new author team.
Alkuperäiskielienglanti
ArtikkeliCD011471
LehtiCochrane database of systematic reviews
Numero6
Sivumäärä4
ISSN1469-493X
DOI - pysyväislinkit
TilaJulkaistu - 8 kesäkuuta 2016

Tieteenalat

  • 3142 Kansanterveystiede, ympäristö ja työterveys

Lainaa tätä

@article{af90062b3813448291468e3947c87480,
title = "Vitamin C for treating atrial fibrillation: [Withdrawal from publication]",
abstract = "The Cochrane editors statement is shown below.However, there is no description why the topic has low priority. We found strong evidence that in RCTs published so far, vitamin C has prevented atrial fibrillation outside of the USA. Thus, was the low priority caused by effects seen only outside of the USA or because vitamin C is not interesting in the view of the Cochrane editors. The manuscript for the Cochrane review is available at: http://www.mv.helsinki.fi/home/hemila/H/HH_2015_CochAF_Protocol.pdf. The review was not rejected because of valid scientific reasons, see responses to reviewer comments at: http://www.mv.helsinki.fi/home/hemila/H/VitC_AF_1308_reviewer_comments.pdf. A shortened version was published in BMC Cardiovascular Disorders: https://doi.org/10.1186/s12872-017-0478-5. ## Reason for withdrawal from publication: The CRG withdrew this protocol as the current author team is unable to progress to the final stage of the review. The editors consider this title as low priority for the current portfolio of the Heart Group and therefore this title is not open to a new author team.",
keywords = "3142 Public health care science, environmental and occupational health",
author = "Harri Hemil{\"a} and Timo Suonsyrj{\"a}",
year = "2016",
month = "6",
day = "8",
doi = "10.1002/14651858.cd011471.pub2",
language = "English",
journal = "Cochrane database of systematic reviews",
issn = "1469-493X",
publisher = "Wiley",
number = "6",

}

Vitamin C for treating atrial fibrillation : [Withdrawal from publication]. / Hemilä, Harri; Suonsyrjä, Timo .

julkaisussa: Cochrane database of systematic reviews, Nro 6, CD011471, 08.06.2016.

Tutkimustuotos: ArtikkelijulkaisuMuu artikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - Vitamin C for treating atrial fibrillation

T2 - [Withdrawal from publication]

AU - Hemilä, Harri

AU - Suonsyrjä, Timo

PY - 2016/6/8

Y1 - 2016/6/8

N2 - The Cochrane editors statement is shown below.However, there is no description why the topic has low priority. We found strong evidence that in RCTs published so far, vitamin C has prevented atrial fibrillation outside of the USA. Thus, was the low priority caused by effects seen only outside of the USA or because vitamin C is not interesting in the view of the Cochrane editors. The manuscript for the Cochrane review is available at: http://www.mv.helsinki.fi/home/hemila/H/HH_2015_CochAF_Protocol.pdf. The review was not rejected because of valid scientific reasons, see responses to reviewer comments at: http://www.mv.helsinki.fi/home/hemila/H/VitC_AF_1308_reviewer_comments.pdf. A shortened version was published in BMC Cardiovascular Disorders: https://doi.org/10.1186/s12872-017-0478-5. ## Reason for withdrawal from publication: The CRG withdrew this protocol as the current author team is unable to progress to the final stage of the review. The editors consider this title as low priority for the current portfolio of the Heart Group and therefore this title is not open to a new author team.

AB - The Cochrane editors statement is shown below.However, there is no description why the topic has low priority. We found strong evidence that in RCTs published so far, vitamin C has prevented atrial fibrillation outside of the USA. Thus, was the low priority caused by effects seen only outside of the USA or because vitamin C is not interesting in the view of the Cochrane editors. The manuscript for the Cochrane review is available at: http://www.mv.helsinki.fi/home/hemila/H/HH_2015_CochAF_Protocol.pdf. The review was not rejected because of valid scientific reasons, see responses to reviewer comments at: http://www.mv.helsinki.fi/home/hemila/H/VitC_AF_1308_reviewer_comments.pdf. A shortened version was published in BMC Cardiovascular Disorders: https://doi.org/10.1186/s12872-017-0478-5. ## Reason for withdrawal from publication: The CRG withdrew this protocol as the current author team is unable to progress to the final stage of the review. The editors consider this title as low priority for the current portfolio of the Heart Group and therefore this title is not open to a new author team.

KW - 3142 Public health care science, environmental and occupational health

U2 - 10.1002/14651858.cd011471.pub2

DO - 10.1002/14651858.cd011471.pub2

M3 - Other articles

JO - Cochrane database of systematic reviews

JF - Cochrane database of systematic reviews

SN - 1469-493X

IS - 6

M1 - CD011471

ER -